Entyvio shows high patient persistence after dose frequency reduction

Patients with inflammatory bowel disease who reduced the frequency of Entyvio dosing showed high persistence and low rates of relapse, according to study results.“The [Entyvio (vedolizumab, Takeda)] extended access program (XAP) was initiated to monitor ongoing safety and to provide continued access to vedolizumab for patients who participated in the GEMINI LTS and VERSIFY studies and who were benefiting from vedolizumab maintenance therapy but did not have access to commercial vedolizumab,” Silvio Danese, MD, PhD, head of the IBD Center at Humanitas University, Milan, Italy, andRead More

Share on facebook
Share on twitter
Share on linkedin